During the last session, Spruce Biosciences Inc (NASDAQ:SPRB)’s traded shares were 0.33 million, with the beta value of the company hitting 2.37. At the end of the trading day, the stock’s price was $0.55, reflecting an intraday gain of 3.20% or $0.02. The 52-week high for the SPRB share is $5.95, that puts it down -981.82 from that peak though still a striking 25.45% gain since the share price plummeted to a 52-week low of $0.41. The company’s market capitalization is $22.64M, and the average intraday trading volume over the past 10 days was 0.54 million shares, and the average trade volume was 447.33K shares over the past three months.

Spruce Biosciences Inc (SPRB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.50. SPRB has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.24.

Spruce Biosciences Inc (NASDAQ:SPRB) trade information

Spruce Biosciences Inc (SPRB) registered a 3.20% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.20% in intraday trading to $0.55, hitting a weekly high. The stock’s 5-day price performance is -3.42%, and it has moved by 24.59% in 30 days. Based on these gigs, the overall price performance for the year is -51.05%. The short interest in Spruce Biosciences Inc (NASDAQ:SPRB) is 0.29 million shares and it means that shorts have 0.59 day(s) to cover.

Spruce Biosciences Inc (SPRB) estimates and forecasts

Statistics show that Spruce Biosciences Inc has underperformed its competitors in share price, compared to the industry in which it operates. Spruce Biosciences Inc (SPRB) shares have gone down -26.36% during the last six months, with a year-to-date growth rate less than the industry average at 9.68% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 20.00% this quarter and then drop -4.20% in the quarter after that. In the rating firms’ projections, revenue will decrease -38.30% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.49M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 1.12M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 3.07M and 2.89M respectively. In this case, analysts expect current quarter sales to shrink by -51.50% and then drop by -61.20% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -22.95%. While earnings are projected to return 19.76% in 2024.

SPRB Dividends

Spruce Biosciences Inc is due to release its next quarterly earnings on 2024-Nov-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Spruce Biosciences Inc (NASDAQ:SPRB)’s Major holders

Spruce Biosciences Inc insiders own 7.72% of total outstanding shares while institutional holders control 44.98%, with the float percentage being 48.75%. RIVERVEST VENTURE MANAGEMENT LLC is the largest shareholder of the company, while 43.0 institutions own stock in it. As of 2024-06-30, the company held over 2.94 million shares (or 7.1449% of all shares), a total value of $1.52 million in shares.

The next largest institutional holding, with 2.9 million shares, is of CARLYLE GROUP INC.’s that is approximately 7.0481% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.52 million.